I don't know axegun
since the Philo Human Right Commission announcement came out mid Jan, there's been a lot a of vol thru OGC, but no change in substantials have come out - says big holders aren't selling - and it's been heavy on the short sell list, says to me it's shorts rather than long only selling. the analysts that cover it think it's pretty cheap (even without didipio) at these prices. (not saying a negative govt shift on project wouldn't badly affect share price).
And Didipio is paid for - they have raise all the money. Plus Debt maturity doesn't like an issue either.
either it's an inside sell and Philo govt come out and say "we're delaying this more", "we're changing the rules" etc etc, or it's big private client selling (Goldmans and their have to do what the analysts says approach) which would be a concern, or shorts are are chsing a delay but don't get it, and they have to cover.
I think it's a buy.
- Forums
- ASX - By Stock
- OGC
- thank you mr. bernanke
thank you mr. bernanke, page-9
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OGC (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online